JP5312315B2 - 肝細胞増殖因子に対するヒト化モノクローナル抗体 - Google Patents

肝細胞増殖因子に対するヒト化モノクローナル抗体 Download PDF

Info

Publication number
JP5312315B2
JP5312315B2 JP2009503254A JP2009503254A JP5312315B2 JP 5312315 B2 JP5312315 B2 JP 5312315B2 JP 2009503254 A JP2009503254 A JP 2009503254A JP 2009503254 A JP2009503254 A JP 2009503254A JP 5312315 B2 JP5312315 B2 JP 5312315B2
Authority
JP
Japan
Prior art keywords
humanized
mab
hgf
antibody
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009503254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009532378A5 (enExample
JP2009532378A (ja
Inventor
キュン チン キム，
リーホン ワン，
ハンギル パク，
マキシミリアーノ バスケス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galaxy Biotech LLC
Original Assignee
Galaxy Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galaxy Biotech LLC filed Critical Galaxy Biotech LLC
Publication of JP2009532378A publication Critical patent/JP2009532378A/ja
Publication of JP2009532378A5 publication Critical patent/JP2009532378A5/ja
Application granted granted Critical
Publication of JP5312315B2 publication Critical patent/JP5312315B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2009503254A 2006-04-01 2007-03-28 肝細胞増殖因子に対するヒト化モノクローナル抗体 Expired - Fee Related JP5312315B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78824306P 2006-04-01 2006-04-01
US60/788,243 2006-04-01
PCT/US2007/065385 WO2007115049A2 (en) 2006-04-01 2007-03-28 Humanized monoclonal antibodies to hepatocyte growth factor

Publications (3)

Publication Number Publication Date
JP2009532378A JP2009532378A (ja) 2009-09-10
JP2009532378A5 JP2009532378A5 (enExample) 2011-03-24
JP5312315B2 true JP5312315B2 (ja) 2013-10-09

Family

ID=38564195

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009503254A Expired - Fee Related JP5312315B2 (ja) 2006-04-01 2007-03-28 肝細胞増殖因子に対するヒト化モノクローナル抗体

Country Status (25)

Country Link
US (3) US7632926B2 (enExample)
EP (2) EP2476704A3 (enExample)
JP (1) JP5312315B2 (enExample)
KR (1) KR101516289B1 (enExample)
CN (2) CN101415811B (enExample)
AR (1) AR059922A1 (enExample)
AU (1) AU2007233242B2 (enExample)
BR (1) BRPI0709932A2 (enExample)
CA (1) CA2645358C (enExample)
CO (1) CO6140067A2 (enExample)
CR (1) CR10308A (enExample)
ES (1) ES2465668T3 (enExample)
GE (1) GEP20125517B (enExample)
IL (1) IL194221A (enExample)
MA (1) MA30382B1 (enExample)
MX (1) MX2008012619A (enExample)
MY (1) MY145042A (enExample)
NO (1) NO20084539L (enExample)
NZ (1) NZ571132A (enExample)
PE (1) PE20080008A1 (enExample)
RU (1) RU2461570C2 (enExample)
TW (1) TWI417300B (enExample)
UA (1) UA94452C2 (enExample)
WO (1) WO2007115049A2 (enExample)
ZA (1) ZA200807903B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
EA015363B1 (ru) 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
RU2007146986A (ru) * 2005-06-02 2009-06-27 ГЭЛЭКСИ БАЙОТЕК, ЭлЭлСи (US) Способы лечения опухолей головного мозга с использованием антител
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
MX2008015138A (es) 2006-06-02 2009-01-28 Aveo Pharmaceuticals Inc Proteinas de union al factor de crecimiento de hepatocitos (fch).
US7649083B2 (en) 2006-06-02 2010-01-19 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
SG188802A1 (en) * 2008-03-06 2013-04-30 Genentech Inc Combination therapy with c-met and egfr antagonists
US9132587B2 (en) * 2008-04-10 2015-09-15 Stratasys Ltd. System and method for three dimensional model printing
TW200948380A (en) * 2008-04-11 2009-12-01 Galaxy Biotech Llc Combination of HGF inhibitor and PTEN agonist to treat cancer
US20110217294A1 (en) * 2008-04-11 2011-09-08 Daniel Fults Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
PE20091827A1 (es) * 2008-04-11 2009-11-20 Galaxy Biotech Llc Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer
WO2009140549A1 (en) * 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
KR101590495B1 (ko) 2008-05-29 2016-02-01 갤럭시 바이오테크, 엘엘씨 염기성 섬유모세포 성장 인자에 대한 모노클로날 항체
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
DK3290052T3 (da) 2008-11-07 2020-02-03 Galaxy Biotech Llc Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2
WO2010071208A1 (ja) 2008-12-19 2010-06-24 武田薬品工業株式会社 抗体の精製方法
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
EP2435478A1 (en) * 2009-05-28 2012-04-04 Glaxo Group Limited Antigen-binding proteins
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
EP3904391B1 (en) 2010-03-10 2024-07-10 Genmab A/S Monoclonal antibodies against c-met
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
WO2012044577A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
MX2013005847A (es) * 2010-11-24 2013-12-12 Glaxo Group Ltd Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
CA2847245A1 (en) 2011-09-09 2013-03-14 Amgen Inc. Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
US9062104B2 (en) 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
TW201444868A (zh) * 2013-03-14 2014-12-01 Alder Biopharmaceuticals Inc Ｈｇｆ抗體及其組成物
US9732150B2 (en) 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
MX391162B (es) 2015-10-30 2025-03-21 Galaxy Biotech Llc Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5
RU2756275C2 (ru) 2016-03-01 2021-09-29 Юссум Рисёрч Девелопмент Компани Оф Зэ Хибру Юниверсити Оф Иерусалим Лтд. Антитела, специфические к рецептору полиовируса (pvr) человека
AU2020327537A1 (en) 2019-08-12 2022-03-03 Interna Technologies B.V. New treatments involving miRNA-193a
KR20220082007A (ko) 2019-10-08 2022-06-16 넥틴 테라퓨틱스 리미티드 폴리오바이러스 수용체(pvr)에 대한 항체 및 이의 용도
US20230136088A1 (en) 2020-02-28 2023-05-04 Interna Technologies B.V. miRNA-193a for Promoting Immunogenic Cell Death
CN113980129B (zh) * 2021-01-15 2023-07-28 东大生物技术(苏州)有限公司 一组il-11单克隆抗体及其医药用途
CN119285785B (zh) * 2024-09-26 2025-04-18 武汉奥科博泰生物科技有限公司 一种抗d-二聚体单克隆抗体及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2564486B2 (ja) 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5646036A (en) 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
ATE465257T1 (de) 1996-07-03 2010-05-15 Genentech Inc Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
ATE335764T1 (de) * 1999-05-17 2006-09-15 Avi Biopharma Inc Spezifische antikörper gegen humanes choriongonadotropin hormone und deren verwendung in therapie und diagnose
WO2001034650A1 (en) 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
US20050075488A1 (en) 2001-07-26 2005-04-07 Bright Stuart Willis Interleukin-1 beta antibodies
WO2003057155A2 (en) 2001-12-27 2003-07-17 Van Andel Research Institute Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
WO2004019991A2 (en) 2002-08-30 2004-03-11 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
AU2003900180A0 (en) * 2003-01-16 2003-01-30 Silverbrook Research Pty Ltd Method and apparatus (dam001)
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
WO2005001486A1 (en) 2003-06-06 2005-01-06 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
US20070020234A1 (en) 2003-07-07 2007-01-25 Vande Woude George F Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
EA015363B1 (ru) 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
KR20060079227A (ko) 2003-09-18 2006-07-05 코닌클리케 필립스 일렉트로닉스 엔.브이. 정보매체와, 그 정보매체에 저장된 데이터 판독 시스템
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
KR100556660B1 (ko) * 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
WO2005079489A2 (en) * 2004-02-17 2005-09-01 Science & Technology Corporation @ Unm Method of treating cancer and identifying novel anti-ancer compounds
CA2572331A1 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
RU2007146986A (ru) 2005-06-02 2009-06-27 ГЭЛЭКСИ БАЙОТЕК, ЭлЭлСи (US) Способы лечения опухолей головного мозга с использованием антител
WO2007056523A2 (en) * 2005-11-08 2007-05-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for diagnosing and monitoring the progression of cancer
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Also Published As

Publication number Publication date
CN103172736A (zh) 2013-06-26
AR059922A1 (es) 2008-05-07
NO20084539L (no) 2008-10-28
US20080019974A1 (en) 2008-01-24
RU2461570C2 (ru) 2012-09-20
MA30382B1 (fr) 2009-05-04
WO2007115049A2 (en) 2007-10-11
BRPI0709932A2 (pt) 2011-08-02
US20100278815A1 (en) 2010-11-04
HK1121489A1 (en) 2009-04-24
JP2009532378A (ja) 2009-09-10
CA2645358C (en) 2015-05-05
AU2007233242A1 (en) 2007-10-11
CA2645358A1 (en) 2007-10-11
KR20090013777A (ko) 2009-02-05
TW200808828A (en) 2008-02-16
CO6140067A2 (es) 2010-03-19
ZA200807903B (en) 2010-03-31
US8628778B2 (en) 2014-01-14
CN101415811A (zh) 2009-04-22
AU2007233242B2 (en) 2012-04-26
CN101415811B (zh) 2013-01-30
US20140335076A1 (en) 2014-11-13
MY145042A (en) 2011-12-15
MX2008012619A (es) 2008-10-13
UA94452C2 (ru) 2011-05-10
TWI417300B (zh) 2013-12-01
NZ571132A (en) 2012-05-25
EP2016162A4 (en) 2009-11-11
ES2465668T3 (es) 2014-06-06
EP2016162A2 (en) 2009-01-21
CR10308A (es) 2008-10-27
EP2476704A2 (en) 2012-07-18
PE20080008A1 (es) 2008-02-14
US7632926B2 (en) 2009-12-15
IL194221A (en) 2015-11-30
GEP20125517B (en) 2012-05-25
RU2008143318A (ru) 2010-05-10
KR101516289B1 (ko) 2015-05-07
WO2007115049A3 (en) 2008-09-04
EP2016162B1 (en) 2014-04-16
EP2476704A3 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
US8628778B2 (en) Humanized monoclonal antibodies to hepatocyte growth factor
JP4594381B2 (ja) 肝細胞増殖因子に対するモノクローナル抗体
US7220410B2 (en) Monoclonal antibodies to hepatocyte growth factor
US20120076775A1 (en) Combination of HGF Inhibitor and EGF Inhibitor to Treat Cancer
EP2288717B1 (en) Monoclonal antibodies to basic fibroblast growth factor
US20110217294A1 (en) Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
HK1121489B (en) Humanized monoclonal antibodies to hepatocyte growth factor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120723

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120820

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120920

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121025

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130422

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130614

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130702

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees